PUBLISHER: TechNavio | PRODUCT CODE: 1502354
PUBLISHER: TechNavio | PRODUCT CODE: 1502354
Technavio has been monitoring the anti-obesity drugs market and is forecast to grow by USD 18330.1 mn during 2023-2028, accelerating at a CAGR of 14.44% during the forecast period. Our report on the anti-obesity drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing obese population, use of bariatric surgery limited for morbid obesity, and limited number of approved drugs.
Technavio's anti-obesity drugs market is segmented as below:
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 12.32% |
CAGR | 14.44% |
Incremental Value | $18330.1mn |
By Type
By Drug Class
By Geography
This study identifies the research on drugs that target both obesity and type 2 diabetes mellitus as one of the prime reasons driving the anti-obesity drugs market growth during the next few years. Also, awareness about weight management and increase in childhood obesity and morbid obesity incidence will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the anti-obesity drugs market covers the following areas:
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-obesity drugs market vendors that include Alvogen Iceland ehf, Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Empros Pharma AB, ERX Pharmaceuticals Inc., Gelesis Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., LG Chem Ltd., Novo Nordisk AS, Rhythm Pharmaceuticals Inc., SCOHIA PHARMA Inc., VIVUS LLC, and Zydus Lifesciences Ltd.. Also, the anti-obesity drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: